| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Adi Aran | |
| Dalit Cayam-Rand | |||
| P2860 | cites work | Parent-mediated early intervention for young children with autism spectrum disorders (ASD) | Q24197951 |
| Early intensive behavioral intervention (EIBI) for young children with autism spectrum disorders (ASD) | Q24198226 | ||
| Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects | Q24606148 | ||
| Toward an exportable parent training program for disruptive behaviors in autism spectrum disorder | Q24613892 | ||
| The Role of Cannabinoids in Neuroanatomic Alterations in Cannabis Users | Q26768135 | ||
| Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders | Q26823267 | ||
| Adverse health effects of marijuana use | Q26861513 | ||
| Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage | Q27336497 | ||
| Molecular characterization of a peripheral receptor for cannabinoids | Q28298338 | ||
| Placebo-like response in absence of treatment in children with Autism | Q33453967 | ||
| Prevalence and risk factors of maladaptive behaviour in young children with Autistic Disorder | Q33728345 | ||
| Epilepsy and epileptiform EEG: association with autism and language disorders | Q33927352 | ||
| Risperidone in children with autism and serious behavioral problems | Q33960551 | ||
| Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis | Q34005713 | ||
| Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study [corrected]. | Q34141036 | ||
| The pleasures of play: pharmacological insights into social reward mechanisms | Q34159109 | ||
| An update on pharmacotherapy for autism spectrum disorder in children and adolescents | Q34458799 | ||
| A systematic review of the antipsychotic properties of cannabidiol in humans | Q34462024 | ||
| Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome | Q34557114 | ||
| Plastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders | Q34557613 | ||
| Appraising the "entourage effect": Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer | Q89235610 | ||
| Sex-specific autistic endophenotypes induced by prenatal exposure to valproic acid involve anandamide signalling | Q89397679 | ||
| Prevalence and Treatment Patterns of Autism Spectrum Disorder in the United States, 2016 | Q90214039 | ||
| Absence of Entourage: Terpenoids Commonly Found in Cannabis sativa Do Not Modulate the Functional Activity of Δ9-THC at Human CB1 and CB2 Receptors | Q90321300 | ||
| Δ-9-Tetrahydrocannabinol and Cannabidiol produce dissociable effects on prefrontal cortical executive function and regulation of affective behaviors | Q90412271 | ||
| Consequences of Perinatal Cannabis Exposure | Q90660691 | ||
| Cannabidiol Administration Prevents Hypoxia-Ischemia-Induced Hypomyelination in Newborn Rats | Q90704777 | ||
| Cannabinoid Exposure via Lactation in Rats Disrupts Perinatal Programming of the Gamma-Aminobutyric Acid Trajectory and Select Early-Life Behaviors | Q90948570 | ||
| Cannabinoid-Based Therapies and Brain Development: Potential Harmful Effect of Early Modulation of the Endocannabinoid System | Q90954364 | ||
| Preclinical safety and efficacy of cannabidivarin for early life seizures | Q91003343 | ||
| Adolescent neurodevelopment and substance use: Receptor expression and behavioral consequences | Q91210455 | ||
| Efficacy and adverse event profile of cannabidiol and medicinal cannabis for treatment-resistant epilepsy: Systematic review and meta-analysis | Q91297514 | ||
| Effects of CBD-Enriched Cannabis sativa Extract on Autism Spectrum Disorder Symptoms: An Observational Study of 18 Participants Undergoing Compassionate Use | Q91316496 | ||
| Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results | Q91513025 | ||
| Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder | Q91539357 | ||
| Exposure to cannabinoids can lead to persistent cognitive and psychiatric disorders | Q91822788 | ||
| Cannabis Use in Children With Pantothenate Kinase-Associated Neurodegeneration | Q91862499 | ||
| Terpenoids and Phytocannabinoids Co-Produced in Cannabis Sativa Strains Show Specific Interaction for Cell Cytotoxic Activity | Q92783084 | ||
| The "Entourage Effect": Terpenes Coupled with Cannabinoids for the Treatment of Mood Disorders and Anxiety Disorders | Q93082735 | ||
| Evaluation of the emotional phenotype and serotonergic neurotransmission of fatty acid amide hydrolase-deficient mice | Q34608846 | ||
| Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation? | Q34676610 | ||
| Preschool children with intellectual disability: syndrome specificity, behaviour problems, and maternal well-being | Q34773070 | ||
| Problem behavior interventions for young children with autism: a research synthesis | Q35015484 | ||
| Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial | Q35125984 | ||
| Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users | Q35431094 | ||
| Rimonabant effects on anxiety induced by simulated public speaking in healthy humans: a preliminary report | Q35962896 | ||
| Prevalence and Predictors of Complementary and Alternative Medicine Use in a Large Insured Sample of Children with Autism Spectrum Disorders | Q36036144 | ||
| Estimation of the burden of active and life-time epilepsy: a meta-analytic approach | Q36135562 | ||
| Endocannabinoid signaling mediates oxytocin-driven social reward | Q36300201 | ||
| Endocannabinoids in amygdala and nucleus accumbens mediate social play reward in adolescent rats. | Q36395277 | ||
| Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity | Q36546326 | ||
| Phencyclidine-induced social withdrawal results from deficient stimulation of cannabinoid CB₁ receptors: implications for schizophrenia. | Q37030178 | ||
| Cannabinoid modulation of amygdala reactivity to social signals of threat in humans | Q37132683 | ||
| The clinical effectiveness of different parenting programmes for children with conduct problems: a systematic review of randomised controlled trials | Q37139119 | ||
| Early Cannabis Use, Polygenic Risk Score for Schizophrenia and Brain Maturation in Adolescence | Q37360523 | ||
| Effects of risperidone and parent training on adaptive functioning in children with pervasive developmental disorders and serious behavioral problems | Q37616011 | ||
| Frontotemporal dementia: what can the behavioral variant teach us about human brain organization? | Q37889021 | ||
| Drug-refractory aggression, self-injurious behavior, and severe tantrums in autism spectrum disorders: a chart review study | Q38191299 | ||
| Initial severity and efficacy of risperidone in autism: Results from the RUPP trial. | Q38396854 | ||
| Effect of parent training vs parent education on behavioral problems in children with autism spectrum disorder: a randomized clinical trial | Q38412773 | ||
| The relationship between cannabidiol and psychosis: A review | Q38467153 | ||
| Mood Stabilizers in Children and Adolescents With Autism Spectrum Disorders | Q38586358 | ||
| Atypical antipsychotics for disruptive behaviour disorders in children and youths | Q38632745 | ||
| Psychopharmacological interventions in autism spectrum disorder | Q38739577 | ||
| Cannabinoids: Medical implications | Q38749077 | ||
| Evidence for the Risks and Consequences of Adolescent Cannabis Exposure | Q38755199 | ||
| Cannabis and epilepsy: An ancient treatment returns to the fore | Q39042588 | ||
| Autism, epilepsy, and synaptopathies: a not rare association | Q39271726 | ||
| Psychopathology in children and adolescents with autism compared to young people with intellectual disability | Q39764963 | ||
| Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial | Q40151883 | ||
| Systems analysis of stress and positive perceptions in mothers and fathers of pre-school children with autism | Q40386986 | ||
| An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity | Q41012471 | ||
| Prevalence and correlates of use of complementary and alternative medicine in children with autism spectrum disorder in Europe | Q41099553 | ||
| The Endocannabinoid System and Autism Spectrum Disorders: Insights from Animal Models. | Q41660878 | ||
| Hashish. I. The structure of cannabidiol | Q42239859 | ||
| Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain | Q42451047 | ||
| Medical Cannabinoids in Children and Adolescents: A Systematic Review | Q42698526 | ||
| Evidence for a common endocannabinoid-related pathomechanism in autism spectrum disorders | Q43628480 | ||
| Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability | Q44208964 | ||
| High rates of psychiatric co-morbidity in individuals with Asperger's disorder | Q44517327 | ||
| The Effect of Marijuana on Small Group Process | Q44869661 | ||
| Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders | Q45113253 | ||
| Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats. | Q45927862 | ||
| Treating a novel plasticity defect rescues episodic memory in Fragile X model mice | Q46229249 | ||
| Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months | Q46580886 | ||
| Treatment Outcomes in Patients with Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs: A 30-Year Longitudinal Cohort Study | Q47245856 | ||
| Emotional and behavioural problems in children with autism spectrum disorder | Q47290593 | ||
| Comparing rates of psychiatric and behavior disorders in adolescents and young adults with severe intellectual disability with and without autism | Q48592285 | ||
| Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being | Q48821406 | ||
| Aggression in children and adolescents with ASD: prevalence and risk factors. | Q50301804 | ||
| Risperidone and adaptive behavior in children with autism. | Q50304198 | ||
| The impact of behaviour problems on caregiver stress in young people with autism spectrum disorders. | Q50304778 | ||
| Patterns of emotional and behavioural disturbance associated with autistic traits in young people with severe intellectual disabilities and challenging behaviours. | Q50305438 | ||
| The impact of parenting stress: a meta-analysis of studies comparing the experience of parenting stress in parents of children with and without autism spectrum disorder. | Q50306135 | ||
| Psychiatric symptoms in preschool children with PDD and clinic and comparison samples. | Q50307500 | ||
| Social and psychiatric functioning in adolescents with Asperger syndrome compared with conduct disorder. | Q50312473 | ||
| Determinants of stress in parents of children with autism spectrum disorders. | Q50345033 | ||
| Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. | Q50890840 | ||
| Marijuana and hostility in a small-group setting. | Q51291199 | ||
| Marijuana Intoxication : Common Experiences | Q51329739 | ||
| Plasma anandamide concentrations are lower in children with autism spectrum disorder. | Q52643582 | ||
| Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial. | Q52750107 | ||
| Effective treatment of spasticity using dronabinol in pediatric palliative care. | Q52981828 | ||
| Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems-A Retrospective Feasibility Study | Q58088545 | ||
| Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis | Q58613951 | ||
| Altered Amygdala Excitation and CB1 Receptor Modulation of Aggressive Behavior in the Neuroligin-3 Mouse Model of Autism | Q58801901 | ||
| Cannabis consumption and psychosis or schizophrenia development | Q60632683 | ||
| Real life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy | Q60907594 | ||
| Some Prospective Alternatives for Treating Pain: The Endocannabinoid System and Its Putative Receptors GPR18 and GPR55 | Q60916595 | ||
| Oral Cannabidiol Use in Children With Autism Spectrum Disorder to Treat Related Symptoms and Co-morbidities | Q61449918 | ||
| The Case for the Entourage Effect and Conventional Breeding of Clinical Cannabis: No "Strain," No Gain | Q61449942 | ||
| Lower circulating endocannabinoid levels in children with autism spectrum disorder | Q61806317 | ||
| Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results | Q62868096 | ||
| Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome | Q62868130 | ||
| The entourage effect of the phytocannabinoids | Q86893365 | ||
| Medical Cannabis for Pediatric Moderate to Severe Complex Motor Disorders | Q88689235 | ||
| P433 | issue | 1 | |
| P577 | publication date | 2020-01-30 | |
| P1433 | published in | Rambam Maimonides Medical Journal | Q18209815 |
| P1476 | title | Medical Cannabis in Children | |
| P478 | volume | 11 |
Search more.